Cellebrite DI Ltd. (NASDAQ:CLBT – Get Free Report) has been given an average rating of “Moderate Buy” by the four brokerages that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation and three have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $21.00.
A number of brokerages have recently issued reports on CLBT. Needham & Company LLC dropped their price objective on Cellebrite DI from $24.00 to $18.00 and set a “buy” rating on the stock in a research note on Thursday, August 14th. Wall Street Zen upgraded Cellebrite DI from a “hold” rating to a “buy” rating in a report on Friday, September 26th. Lake Street Capital cut their price target on Cellebrite DI from $24.00 to $22.00 and set a “buy” rating on the stock in a report on Friday, August 15th. JPMorgan Chase & Co. raised their price objective on shares of Cellebrite DI from $20.00 to $23.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 24th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Cellebrite DI in a research report on Wednesday, October 8th.
View Our Latest Analysis on Cellebrite DI
Hedge Funds Weigh In On Cellebrite DI
Cellebrite DI Stock Performance
Cellebrite DI stock opened at $15.40 on Monday. The firm has a market cap of $3.69 billion, a price-to-earnings ratio of -20.26, a PEG ratio of 3.16 and a beta of 1.28. Cellebrite DI has a 52-week low of $13.10 and a 52-week high of $26.30. The firm has a 50 day moving average price of $17.76 and a two-hundred day moving average price of $16.78.
Cellebrite DI (NASDAQ:CLBT – Get Free Report) last posted its quarterly earnings data on Thursday, August 14th. The company reported $0.12 EPS for the quarter, beating analysts’ consensus estimates of $0.11 by $0.01. Cellebrite DI had a negative net margin of 34.56% and a positive return on equity of 23.92%. The company had revenue of $113.28 million for the quarter, compared to analyst estimates of $112.33 million. During the same period in the prior year, the firm posted $0.10 EPS. The company’s quarterly revenue was up 18.4% on a year-over-year basis. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, equities research analysts predict that Cellebrite DI will post 0.3 EPS for the current fiscal year.
Cellebrite DI Company Profile
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Read More
- Five stocks we like better than Cellebrite DI
- 3 Tickers Leading a Meme Stock Revival
- OpenAI’s Restructuring Sets up What Could Be the Biggest IPO Ever
- What is a Special Dividend?
- 2 Rare Earth Stocks the U.S. Government Doesn’t Want to Fail
- How to Calculate Retirement Income: MarketBeat’s Calculator
- CrowdStrike Partners With CoreWeave But Investors Sell the News
Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.
